Weighty Issues in Type 2 diabetes
|
|
- Erin Hancock
- 5 years ago
- Views:
Transcription
1 Weighty Issues in Type 2 diabetes Joseph Proietto University of Melbourne Department of Medicine and Department of Diabetes and Endocrinology Austin Health j.proietto@unimelb.edu.au
2 Dennis Wilson 2
3 Declaration of Possible Conflicts of Interest JP is or was a member of the Medical Advisory Boards for: Exenatide (Byetta) for AstraZeneca Liraglutide (Victoza) for Novo Nordisk Liraglutide 3 mg (Saxenda) for Novo Nordisk Sitagliptin (Januvia) for MSD Dapagliflozin (Forxiga) for AstraZeneca And has given lectures on the management of obesity for inova marketers of Duromine
4 Australian guideline recommendations 1 Lifestyle modification: diet weight control physical activity Metformin SU as monotherapy or combination therapy Acarbose DPP-4 inhibitor # TZD* Associated with increased risk of heart failure, oedema and fractures GLP-1 analogues Insulin SGL-T2 inhibitors 1. Colagiuri et al. National evidence based guideline for blood glucose control in type 2 diabetes. Diabetes Australia and the NHMRC, Canberra Pharmaceutical Benefits Scheme (PBS) EXENATIDE [Accessed ].
5 Obesity Hepatic insulin resistance Peripheral insulin resistance Impaired β cell function in genetically susceptible individuals Type 2 Diabetes
6 It follows that: The best way to treat type 2 diabetes is to achieve weight loss
7 Dixon JB, Playfair J, Skinner S, Proietto J, Schachter LM, Chapman L, Anderson M, Bailey M, and O Brien PE. Surgically Induced Loss Of Weight for management of Type-2 Diabetes: Randomized Trial. JAMA 2008; 299:316-23
8 Gastric Banding
9 Inclusion Criteria BMI Age Type 2 Diabetes diagnosed within the last 2 years No evidence of renal impairment or diabetic retinopathy Understand both treatment options Accept randomization
10 Outcome Measures Proportion achieving diabetes remission defined as all of the following Fasting plasma glucose < 7mmol/l A1c < 6.2 % Not requiring any hypoglycaemic medication or insulin At 2-years after randomization Proportion with A1c levels <7%, and A1c was also examined as a continuous variable Weight
11 Baseline Characteristics Surgical Group (Mean, Median or %) Conventional Therapy Group (Mean, Median or %) Number Age (years) 46.6 (7.4) 47.1 (8.7) Male n (%) 15 (50%) 13 (43%) BMI (kg/m 2 ) 37.0 (2.7) 37.2 (2.5) Weight (kg) (13.8) (14.2) Waist Circumference (cm) (10.2) (10.0) Waist:Hip Ratio 0.96 (0.09) 0.96 (0.10) HbA1c (%) 7.8 (1.2) 7.6 (1.4)
12 Diabetes Remission at 2 years Lifestyle Surgery % weight loss * HbA1c < 7% 50% 87%* % remission 13% (ITT) 73% (ITT)* * P < 0.001
13 But with ~ 23% of the population obese there are not enough surgeons and operating theatres to treat even a small percentage of patients that need treatment. Not everyone wants an operation 13
14 What is the best way to lose weight medically? 14
15 The Lancet Diabetes and Endocrinol 2:
16 Methods Randomly allocated Obese but otherwise healthy participants, years of age Rapid program (12-week intervention) Gradual program (36-week intervention) 12.5% Weight maintenance diet (144 weeks) Phase 1: weight loss Phase 2: weight maintenance
17 Results Variable Baseline characteristics Rapid Group (n=97) Gradual Group (n=103) Age (years) 49.6 ± ± 11.1 Sex (female) 73.2% 75.7% Weight (kg) 96.4 ± ± 14.2 BMI (kg/m 2 ) 35.2 ± ± 4.0 Waist circumference (cm) ± ± 10.0 Hip circumference (cm) ± ± 10.9 Systolic BP (mmhg) ± ± 13.8 Diastolic BP (mmhg) 82.6 ± ± 8.8 Fat mass (kg) 48.5 ± ± 13.1 Mean daily steps 7107 ± ± 3021 Mean ± SD. No significant differences were detect between the two treatment groups (P>0.05 for all comparisons)
18 Results Rate of weight loss during phase 1 for successful participants (mean % change, 95% CI)
19 Achievement of 12.5% weight loss during phase 1 p<0.001 Dropped out: 3 18
20 Does rapid weight loss lead to faster weight regain?
21 Weight regain % during phase 2 Gradual WL group regained 71.2% Rapid WL group regained 70.5% *n=61 in rapid weight loss and n=43 in gradual weight loss group
22 Summary of findings Using rapid weight loss program (VLED): 1. More likely to achieve target weight loss 2. Less likely to drop out 3. No difference in weight regain Why did we find a higher success rate with the stricter diet?
23 Results Phase 1 median (IQR) Beta-hydroxybutyrate concentration at baseline, and 5%, 10% and 15% weight loss * P = 0.035; P< At baseline: gradual weight loss (n=18), rapid weight loss (n=20); At 5%: gradual weight loss (n=16), rapid weight loss (n=19); At 10%: gradual weight loss (n=11), rapid weight loss (n=16); At 15%: gradual weight loss, 5%, 10% and 15% weight loss separated according to treatment groups.
24 How do ketones suppress hunger? 24
25 The brain can metabolise ketones 25
26 26
27 Conclusion The results are.. consistent with the hypothesis that human nervous tissue can metabolize ketones acutely. 27
28 How should rapid weight loss be achieved safely?
29 To achieve rapid weight loss it is necessary to have a large gap between energy intake and energy expenditure. However to obtain the necessary micronutrients it is necessary to have and intake of at least 4920 kj (1200) kcal.
30 VLED Provide only kj ( kcal/day Very low in fat and carbohydrate Supply all the needed vitamins, minerals and amino acids.
31 VLED 1 sachet or bar twice daily (breakfast and lunch) with plenty of water In the evening have a no carbohydrate dinner with protein vegetables and a salad Oil on vegetables and or salad if gall bladder is present Daily exercise
32 Are VLED s safe?
33 Safe year-long use of a very-low-calorie diet for the treatment of severe obesity Priya Sumithran and Joseph Proietto Med J Aust 2008; 188 (6):
34 Does the VLED approach work in patients with type 2 diabetes? 34
35
36 Aims of the study To investigate the efficacy of a VLCD program in reducing weight and adiposity in obese subjects with type 2 diabetes or normal fasting glucose over a 24-week intervention
37 Change in weight n = 51 T2DM: 8.5 ± 1.3 kg vs. CON: 9.4 ± 1.2 kg P = 0.64
38 Tips for using VLED s in patients with Diabetes 1. If the patient with diabetes is on glucose lowering drugs that can cause hypoglycemia (insulin or sulphonylureas) it is essential to tell the patient to reduce the dose in half and to monitor glucose closely the first few days. The doses of these agents are then manipulated to maintain glucose control. 2. Check c-peptide before starting so that you may be able to asses whether stopping insulin is a possibility following substantial weight loss. 38
39 Why has obesity not been tackled earlier for the treatment of Type 2 diabetes? 39
40 Weight change (kg) Diet and behavioural intervention Very-low-calorie diet Modified diet plus behaviour therapy Very-low-calorie diet plus behaviour therapy intervention Years after intervention
41 Why do most subjects regain weight? 41
42 Diagram of the central regulation of body weight (from Proietto J. MJA 195: )
43 Changes in leptin levels with dieting BMI (kg/m 2 ) or Leptin (pmol/dl) BMI Leptin BMI, body mass index Weeks Geldszus et al. Eur J Endocrinol 1996;135:659 62
44 Ghrelin levels after diet-induced weight loss Cummings et al. N Engl J Med 2002;346:
45 Post-breakfast CCK release pre- and post-weight loss Plasma CCK (pmol/l) CCK AUC (pmol/l/4h) p=0.016 Week 0 Week 9 Week 0 Week Time (min) Chearskul et al. Am J Clin Nutrition 2008;87:
46 Body weight is defended Sumithran P et al. N Engl J Med 2011; 365:
47 Residual values (kcal/d) Total, resting and non-resting energy expenditure TEE REE NREE Wt initial Wt loss-recent Wt loss-sustained NREE, non-resting energy expenditure; REE, resting energy expenditure; TEE, total energy expenditure. Rosenbaum M et al. Am J Clin Nutr 2008; 88:
48 What strategies should we adopt to help our patients to maintain weight loss long term?
49 Lifestyle advice Healthy eating Regular Exercise Weigh yourself once weekly in the morning with an empty bladder If you regain 2 kg, restart the intense diet and continue it until you have lost the 2 kg again.
50 Weight Loss Agents : - Saxenda (Liraglutide 3.0 mg) - Phentermine (Duromine) - [Topiramate (Topamax)] [ ] off label use
51 Weight Loss Agents : Major Points about Weight loss medications: Nature combines nine gut and pancreatic hormones and several nutrients to suppress hunger so, it is better to use multiple drugs at their lowest doses to control hunger after weight loss rather than just one drug at a high dose. Because weight is predominantly genetic, the hormonal and energy expenditure changes that occur after weight loss, designed to return the weight to its set point, are long lasting. It follows that drug use has to be long term (life-long).
52 The Team Clinical research Unit Priya Sumithran Cilla Haywood Luke Prendergast Rebecca Sgambellone Kira Edwards Cheryl Adams Nicola Robinson Katrina Purcell Jodie Prendergast Mary Caruana Basic Science Lab Sof Andrikopoulos Barbara Fam Nicole Wong Ben Lamont Salvatore Mangiafico Zheng Ruan Chrisa Xirouchaki Steven Weng Maria Stathopoulos Christo Ioannides
GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationMaintaining weight loss: an ongoing challenge
Priya Sumithran MBBS, FRACP, PhD and Joseph Proietto MBBS, FRACP, PhD University of Melbourne, Department of Medicine (Austin Health), Melbourne, Australia Correspondence: Dr Priya Sumithran Level 2, Boronia
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationPrimary Outcome Results of DiRECT the Diabetes REmission Clinical Trial
Finding a practical management solution for T2DM, in primary care Primary Outcome Results of DiRECT the Diabetes REmission Clinical Trial Mike Lean, Roy Taylor, and the DiRECT Team IDF Abu Dhabi, December
More information8/27/2012. Mississippi s Big Problem. An Epidemic Now Reaching Our Children. What Can We Do?
Mississippi s Big Problem. An Epidemic Now Reaching Our Children What Can We Do? Richard D. deshazo, MD Billy S. Guyton Distinguished Professor Professor of Medicine & Pediatrics University of Mississippi
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationWeight Loss for Young Women - What Works?
Weight Loss for Young Women - What Works? Helen O Connor PhD APD 1 Research Team Hayley Griffin PhD APD 1, Hoi Lun Cheng APD 1, Kieron Rooney PhD 1, Prof Kate Steinbeck MBBS FRACP 2 1. Exercise & Sport
More informationDr Karen McNeil Consultant Endocrinologist
Dr Karen McNeil Consultant Endocrinologist Aged 53 Type 2 Diabetes 2010 HbA1c 7.9% ACR 5.3 mg/mmol What treatment? MF 500 mg bd (misses midday dose) Control Symptoms, BGL Complications DR, DN, PN Associations
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationFor Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity
Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationTreating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition
Treating Type 2 Diabetes by Treating Obesity Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition 2 Center Stage Obesity is currently an epidemic in the United States, with
More informationTHE PERENNIAL STRUGGLE TO LOSE WEIGHT AND MAINTAIN: WHY IS IT SO DIFFICULT?
THE PERENNIAL STRUGGLE TO LOSE WEIGHT AND MAINTAIN: WHY IS IT SO DIFFICULT? Robert Ferraro, MD Medical Director Southwest Endocrinology Associates, PA Diabetes and Weight Management Center OBESITY The
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationObesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationWhat we know about energy balance
What we know about energy balance New understanding on how and why we gain and lose weight Presented by A/Professor Amanda Salis The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders The
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationThe effect of rate of weight loss on long-term weight management: a randomised controlled trial
The effect of rate of weight loss on long-term weight management: a randomised controlled trial Katrina Purcell, Priya Sumithran, Luke A Prendergast, Celestine J Bouniu, Elizabeth Delbridge, Joseph Proietto
More informationObesity and diabetes threaten European quality of life and regional health and social care budgets
Obesity and diabetes threaten European quality of life and regional health and social care budgets Professor Mike Lean 3rd May 2017 Type 2 Diabetes in the 21 st Century A New Treatment Paradigm Professor
More informationThe Physiology of Weight Regulation: Implications for Effective Clinical Care
Roundtable on Obesity Solutions The Physiology of Weight Regulation: Implications for Effective Clinical Care Lee M. Kaplan, MD, PhD Obesity, Metabolism & Nutrition Institute Massachusetts General Hospital
More informationOBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationClinical Update: Popular diets
Clinical Update: Popular diets Scott D. Isaacs, MD, FACP, FACE Adjunct Instructor of Medicine, Emory University School of Medicine Medical Director, Atlanta Endocrine Associates Member, AACE Board of Directors
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationHow do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian
How do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian Developing a specialist weight management programme How did we adapt dietary approaches for
More informationSue Cummings, MS, RD
Starting Principles: Causes of Obesity Obesity is a chronic disease that is: Dietary Causes of Weight Regain SUE CUMMINGS, MS, RD SCUMMINGS1@PARTNERS.ORG both biopsychosocially complex in its origins and
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationThe US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationTake Charge Feel Positive About Nutrition. Marion J. Franz, MS, RD, CDE
Take Charge Feel Positive About Nutrition Marion J. Franz, MS, RD, CDE Questions What questions do you have? What s important? What s controversial? How important is weight loss? What about physical activity?
More informationINJECTABLE THERAPIES IN DIABETES. Barbara Ann McKee Diabetes Specialist Nurse
INJECTABLE THERAPIES IN DIABETES Barbara Ann McKee Diabetes Specialist Nurse 1 Aims of the session Describe the different injectable agents for diabetes and when they would be used. Describe some common
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationInformation Sheet. Weight. Accessible information about weight for adults with an eating disorder
Information Sheet Weight Accessible information about weight for adults with an eating disorder ? Why do I need to restore my body weight? Weight restoration in eating disorders is integral to recovery
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationOBESITY: The Growing Epidemic and its Medical Impact
OBESITY: The Growing Epidemic and its Medical Impact Ray Plodkowski, MD Co-Chief, Chief, of Division of Medical Nutrition, University of Nevada School of Medicine. Chief, Endocrinology & Metabolism, Sachiko
More informationInnovate. Discover. Cure. Type 2 Diabetes what you and your family need to know
1 Innovate. Discover. Cure. Type 2 Diabetes what you and your family need to know Opening comments Steven R. Smith, MD Founding Scientific Director - TRI Professor, metabolic diseases program, Sanford-Burnham
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationKetogenic/Low Carbohydrate diets for weight loss- What s the big deal?
Ketogenic/Low Carbohydrate diets for weight loss- What s the big deal? Presented by Claudia Harper APD Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders The University of Sydney Page
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationEnergy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain
1 Energy balance Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain Special implications Infancy, Illness, Pregnancy & Lactation, Sports Factors affecting energy input neuro-endocrine
More information21 st November
21 st November 2013 Structure What do consumers eat? Prawn nutrition Dietary reference values (HP diets) Appetite control Future research sustainability and health UK Protein intake top 10 (from NDNS survey)
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationOBESITY IN PRIMARY CARE
OBESITY IN PRIMARY CARE Obesity- definition Is a chronic disease In ICD 10 E66 Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a leading
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationOPTIFAST VLCD Program- Pharmacy Training
OPTIFAST VLCD Program- Pharmacy Training OPTIFAST VLCD is a food for special medical purposes for the dietary management of obesity. Must be used under medical supervision. For training purposes only.
More informationAppendix 1. Evidence summary
Appendix 1. Evidence summary NG7 01. Recommendation 1 Encourage people to make changes in line with existing advice ES 1.17, 1.31, 1.32, 1.33, 1.37, 1.40, 1.50, 2.7, 2.8, 2.10; IDE New evidence related
More informationWhy Obese People are Unable to Keep Weight Off After Losing It
Why Obese People are Unable to Keep Weight Off After Losing It Robert E. Ratner, MD Chief Scientific and Medical Officer American Diabetes Association I have no Pertinent Financial Disclosures Change in
More informationGetting Ahead of the Curve in the Trouble with Fat
Getting Ahead of the Curve in the Trouble with Fat Zhaoping Li, M.D., Ph.D. Professor of Medicine David Geffen School of Medicine, UCLA VA Greater Los Angeles Health Care System Obesity Pandemic Predicted
More information3/17/2017. What is Fiber? Fiber and Protein in Your Diet. Fiber Intake Recommendations. Fiber, Satiety, and Weight Relationships.
What is Fiber? Dietary Fiber consists of nondigestible carbohydrates. Fiber has many roles such as delaying gastric emptying and reducing blood cholesterol concentrations. Fiber and Protein in Your Diet
More informationSubject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119
Acarbose, diabetes prevention trials 32, 33, 40 42 Accelerator hypothesis accelerators beta cell autoimmunity 140, 141, 147, 150, 151 insulin resistance 140, 142 144, 150 obesity 145 148 diabetes risk
More informationObjectives. Define satiety and satiation Summarize the satiety cascade Describe potential dietary interventions aimed at improving satiety
Foods that Fill Monica Esquivel PhD RDN Assistant Professor, Dietetics Program Director Department of Human Nutrition, Food and Animal Sciences November 8, 2017 Objectives Define satiety and satiation
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationThe three things every surgeon should tell their obese patient
Bariatric and Private Practice Dietitian The three things every surgeon should tell their obese patient Chermside Medical Complex Holy Spirit Northside Private Hospital Red Hill Doctors Surgery Obesity
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationLong-Term Persistence of Hormonal Adaptations to Weight Loss
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Long-Term Persistence of Hormonal Adaptations to Weight Loss Priya Sumithran, M.B., B.S., Luke A. Prendergast, Ph.D., Elizabeth Delbridge,
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider
More informationWhy Obesity Is A Chronic Disease
Why Obesity Is A Chronic Disease Arya M Sharma, MD, FRCP(C) Professor of Medicine Chair in Obesity Research & Management University of Alberta Edmonton, AB, Canada www.drsharma.ca Global Obesity Map 2014
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More information